TMS Co., Ltd. (JP:4891) has released an update.
TMS Co., Ltd. has secured a U.S. patent for a new treatment for acute kidney injury using compounds including TMS-008, further strengthening its global intellectual property portfolio alongside recent grants in Japan and China. This development highlights TMS’s commitment to advancing innovative treatments in areas with high unmet medical needs.
For further insights into JP:4891 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Alphabet’s Waymo Expands Robotaxi Rides in Los Angeles to All Passengers
- Pfizer Considers Selling Hospital Unit to Free Up Cash and Reduce Debt
- Trump’s Win Is Good News for Alphabet Stock, Says Top Investor
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
